Stephen Harbin - Oncorus COO Staff
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
Insider
Stephen Harbin is COO Staff of Oncorus
| Age | 64 |
| Phone | 857 320 6400 |
| Web | https://www.oncorus.com |
Oncorus Management Efficiency
The company has return on total asset (ROA) of (0.3224) % which means that it has lost $0.3224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2456) %, meaning that it created substantial loss on money invested by shareholders. Oncorus' management efficiency ratios could be used to measure how well Oncorus manages its routine affairs as well as how well it operates its assets and liabilities.Oncorus currently holds 70.65 M in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies. Oncorus has a current ratio of 6.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncorus' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Martina BS | Pyxis Oncology | 59 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Pamela MBA | Pyxis Oncology | 62 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| David Dornan | Elevation Oncology | 46 | |
| Jan Pinkas | Pyxis Oncology | N/A | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| MBA MBA | Pyxis Oncology | 51 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
Management Performance
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 |
Oncorus Leadership Team
Elected by the shareholders, the Oncorus' board of directors comprises two types of representatives: Oncorus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncorus. The board's role is to monitor Oncorus' management team and ensure that shareholders' interests are well served. Oncorus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncorus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard MBA, Chief CFO | ||
| Brian Shea, Director Sec | ||
| Chris German, Controller | ||
| Stephen Harbin, COO Staff | ||
| Mitchell Finer, NonEx Chairman | ||
| John MD, Chief Officer |
Oncorus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncorus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 | |||
| Current Valuation | 25.71 M | |||
| Shares Outstanding | 26.09 M | |||
| Shares Owned By Insiders | 12.69 % | |||
| Shares Owned By Institutions | 55.29 % | |||
| Number Of Shares Shorted | 447.72 K | |||
| Price To Book | 0.13 X | |||
| EBITDA | (75.42 M) | |||
| Net Income | (77.42 M) |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |